Eli Lilly insulin (various forms)
What is this? This is insulin made by Eli Lilly. It comes as a liquid or a mix you inject under the skin.
What's happening? Some forms of this insulin are in short supply right now.
Does this affect me? If you use Eli Lilly insulin, you may be affected.
What should I do? Talk to your pharmacist or doctor before changing your dose or brand.
🤖 Denne letforståelige oversigt er automatisk genereret ud fra den officielle meddelelse fra myndigheden ved hjælp af AI. Den er udelukkende til generel information — ikke medicinsk rådgivning. Vedrørende beslutninger om din sundhed, skal du altid konsultere en farmaceut eller læge og læse den officielle kilde, der er linket nedenfor.
📋 Fra den officielle meddelelse fra myndigheden
Opdateret for 1 uge siden- Først udgivet
- 23/03/2026
- Berørte lægemidler
- Eli Lilly insulin (various forms)
- Lagerstatus
- Ongoing
- Tilgængelighed af alternativer
- Yes
- Berørte lægemiddelformer
- Solution for injectionSuspension for injection
Sideindhold
Mangel på lager
Eli Lilly is discontinuing some of its insulin presentations (containing human insulin, insulin lispro and insulin glargine) across selected countries. The specific products affected and the timelines for their withdrawal differ across EU/EEA countries. All discontinuations are expected to occur before Q2 2027, after which the affected insulin presentations will no longer be available.
This is in addition to Humalog Mix25 (25% insulin lispro and 75% insulin lispro protamine, 100 units/ml suspension for injection, vial) which has already been discontinued in all EU/EEA countries where it was marketed.
Insulin medicines are used to treat patients who have diabetes and need insulin to help control their blood glucose (sugar) level.
For information on the use of the medicines please refer to the respective medicine overview pages on EMA’s website.
For more details and up-to-date information on the availability of individual insulins, consult your country’s shortage register or contact your national competent authority.
The company Eli Lilly has decided to stop marketing some of its insulin medicines for commercial reasons. This decision is not related to a quality defect or safety issue.
The discontinuations affect Member States differently. For more details, consult your country’s shortage register or contact your national competent authority.
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party) are closely monitoring the supply situation and engaging with the marketing authorisation holder and other stakeholders to mitigate the impact of the planned discontinuations.
The SPOC Working Party Supports EMA’s MSSG and monitors and reports events that could affect the supply of medicines in the EU.
- For information specific to your country, please consult your national shortage register or contact your national competent authority.
- In affected Member States, healthcare professionals will receive a shortage communication letter with details on the impacted insulins and recommended actions.
- Where applicable, healthcare professionals should transition patients currently using any of the affected insulins to suitable alternatives, in line with existing guidance and their clinical judgement.
- Healthcare professionals should ensure that all patients are counselled on any changes in the new insulin regimen including the need to change dose and/or usage of the new insulin delivery system and additional glucose monitoring.
- Close glucose monitoring is recommended when the patient is switched to another type or brand of insulin and in the initial weeks thereafter, especially in pregnant women and children who may need closer monitoring than the general population. The risk of hypoglycaemia may be higher in these populations.
- Healthcare professionals may also contact relevant organisations for further information. A list of European not-for-profit organisations EMA engages with can be found on the EMA website.
- For information specific to your country, please consult your national shortage register or contact your healthcare professional.
- Your healthcare professional will advise you if any of the insulins you are using are affected by the discontinuation and will switch you to an alternative insulin, if needed.
- If your healthcare professional switches your insulin they will explain any changes to you and ensure that you are given adequate training on using any new insulin delivery system.
- If you are being switched, you may need to closely monitor your glucose levels during the transfer to another type or brand of insulin and in the initial weeks thereafter. This applies especially if you are pregnant or under 18 years of age, as you may be at higher risk of hypoglycaemia.
- If you have any questions, speak to your doctor or pharmacist.
- You may also contact relevant patients’ organisations for further information or support. A list of European not-for-profit organisations that EMA engages with can be found on the EMA website.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Årsag til mangel
The company Eli Lilly has decided to stop marketing some of its insulin medicines for commercial reasons. This decision is not related to a quality defect or safety issue.
Berørte medlemsstater
The discontinuations affect Member States differently. For more details, consult your country’s shortage register or contact your national competent authority.
Overvågning af mangel
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party) are closely monitoring the supply situation and engaging with the marketing authorisation holder and other stakeholders to mitigate the impact of the planned discontinuations.
The SPOC Working Party Supports EMA’s MSSG and monitors and reports events that could affect the supply of medicines in the EU.
Anbefalinger til sundhedspersonale
- For information specific to your country, please consult your national shortage register or contact your national competent authority.
- In affected Member States, healthcare professionals will receive a shortage communication letter with details on the impacted insulins and recommended actions.
- Where applicable, healthcare professionals should transition patients currently using any of the affected insulins to suitable alternatives, in line with existing guidance and their clinical judgement.
- Healthcare professionals should ensure that all patients are counselled on any changes in the new insulin regimen including the need to change dose and/or usage of the new insulin delivery system and additional glucose monitoring.
- Close glucose monitoring is recommended when the patient is switched to another type or brand of insulin and in the initial weeks thereafter, especially in pregnant women and children who may need closer monitoring than the general population. The risk of hypoglycaemia may be higher in these populations.
- Healthcare professionals may also contact relevant organisations for further information. A list of European not-for-profit organisations EMA engages with can be found on the EMA website.
Anbefalinger til patienter og pårørende
- For information specific to your country, please consult your national shortage register or contact your healthcare professional.
- Your healthcare professional will advise you if any of the insulins you are using are affected by the discontinuation and will switch you to an alternative insulin, if needed.
- If your healthcare professional switches your insulin they will explain any changes to you and ensure that you are given adequate training on using any new insulin delivery system.
- If you are being switched, you may need to closely monitor your glucose levels during the transfer to another type or brand of insulin and in the initial weeks thereafter. This applies especially if you are pregnant or under 18 years of age, as you may be at higher risk of hypoglycaemia.
- If you have any questions, speak to your doctor or pharmacist.
- You may also contact relevant patients’ organisations for further information or support. A list of European not-for-profit organisations that EMA engages with can be found on the EMA website.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Nøgleoplysninger
- Medicines affected
- Eli Lilly insulin (various forms)
- Supply shortage status
- Ongoing
- Pharmaceutical forms affected
- Solution for injection
- Suspension for injection
- Availability of alternatives
- Yes
Nøgledatoer
- First published
Relateret medicinsk information
🔬 Medicinske/tekniske detaljer Til fagfolk
Forms: Solution for injection;Suspension for injection · Alternatives: Yes
Alle oplysninger på denne side stammer fra den officielle meddelelse fra myndighederne. Vi oversætter og opsummerer den; vi tilføjer eller redigerer ikke fakta.
